0.15
+0(+0.00%)
Currency In USD
| Previous Close | 0.15 |
| Open | 0.15 |
| Day High | 0.15 |
| Day Low | 0.15 |
| 52-Week High | 4.55 |
| 52-Week Low | 0.12 |
| Volume | 4,000 |
| Average Volume | 375,105 |
| Market Cap | 1.25M |
| PE | -0.04 |
| EPS | -4.12 |
| Moving Average 50 Days | 0.16 |
| Moving Average 200 Days | 0.81 |
| Change | 0 |
If you invested $1000 in Bio-Path Holdings, Inc. (BPTH) 10 years ago, it would be worth $0.03 as of May 05, 2025 at a share price of $0.15. Whereas If you bought $1000 worth of Bio-Path Holdings, Inc. (BPTH) shares 5 years ago, it would be worth $1.63 as of May 05, 2025 at a share price of $0.15.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
GlobeNewswire Inc.
May 01, 2025 11:00 AM GMT
Data suggest BP1001-A prevents fatty acid-induced insulin resistance in cellsHOUSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antis
Bio-Path Holdings Reports Full Year 2024 Financial Results
GlobeNewswire Inc.
Mar 28, 2025 11:00 AM GMT
Reports Continued Progress Across Both Obesity and Oncology FranchisesHOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle techn
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
GlobeNewswire Inc.
Mar 18, 2025 11:00 AM GMT
Recent Pre-Clinical Studies Showed BP1001-A Attenuated Fatty Acid-Induced Insulin Resistance and Restored Insulin Sensitivity in Muscle Progenitor and Skeletal Muscle Fiber Cell ModelsHOUSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, I